Live Breaking News & Updates on Lenalidomide Vi

Stay updated with breaking news from Lenalidomide vi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Current Treatment Options in Second-line FL

Experts on follicular lymphoma discuss second-line treatment options available for patients. ....

Recent Updates , Follicular Lymphoma , Mantle Cell Lymphoma , Treatment Options , Second Line Therapy , Overall Survival , Cart Cell Therapy , T Cell Engager , Cytokine Release Syndrome ,

Results of the Phase III Randomized IsKia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Francesca Gay, MD, PhD, presents results from the phase III randomized IsKia trial investigating isatuximab-carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in patients with newly diagnosed multiple myeloma. ....

United States , San Diego , Iskia Trial , Pre Transplant Induction , Post Transplant Consolidation , Newly Diagnosed Multiple Myeloma , Multiple Myeloma , Iskia Study , Newly Diagnosed Mm ,

D-VRd Improves PFS in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant, daratumumab, bortezomib, lenalidomide, and dexamethasone consolidation and daratumumab/lenalidomide maintenance prolonged progression-free survival in patients with newly diagnosed, transplant-eligible multiple myeloma. ....

Subcutaneous Daratumumab , Autologous Stem Cell Transplant , Nd Dexamethasone Consolidation , Daratumumab Lenalidomide Maintenance , Patients With Newly Diagnosed , Transplant Eligible Multiple Myeloma , Perseus Trial , Pieter Sonneveld , Erasmus Mc Cancer Institute ,

Isa-KRd Produces Deep, Durable Response Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

The addition of isatuximab-irfc to carfilzomib, lenalidomide, and dexamethasone was well tolerated and elicited a 100% objective response rate in standard- and high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. ....

Elizabethk Odonnell , Dana Farber Cancer Institute , Drug Administration , Professor Of Medicine At Harvard Medical School , Early Detection , Assistant Professor , Harvard Medical School , Ash Annual Meeting , Phase 2 Skylark Trial Nct04430894 , Newly Diagnosed Multiple Myeloma Ndmm , Isatuximab Irfc ,

Time to Stop Routine Maintenance Therapy in Myeloma?

Physicians may need to rethink maintenance with lenalidomide (Revlimid and generics) for multiple myeloma. ....

United States , New York , Memorial Sloan Kettering Cancer Center , Nikhil Munshi , Sergio Giralt , Benjamin Derman , Shaji Kumar , International Myeloma Working Group , University Of Alabama At Birmingham , University Of Chicago , National Comprehensive Cancer Network Multiple Myeloma Guidelines , Harvard Medical School , Lancet Haematology , Luciano Costa , New England Journal , Mayo Clinic , International Myeloma Working , Multiple Myeloma , Plasma Cell Myeloma , Biologic Therapy , Transplantation Of Bone Marrow , Bone Marrow Transplantation , Bone Marrow Transplant , Transplantation Of Stem Cells , Ransplantation Of Hematopoietic Stem Cells , Hematopoietic Stem Cell Transplant ,